

Acute Coronary Syndromes Guideline Committee meeting 5

Date: 24 January 2019

Location: Royal College of Physicians, London

Minutes: Final

Committee members present:	
Margaret Lally (Chair)	Present for notes 1 – 8
Simon Corbett (Topic Advisor)	Present for notes 1 – 8
Farrah Al-Ghita	Present for notes 1 – 8
Christopher Cassidy	Present for notes 1 – 8
Ewan Gittins	Present for notes 1 – 8
Lance Goodman	Present for notes 1 – 8
Jaydeep Sarma	Present for notes 1 – 8
Alex Sharp	Present for notes 1 – 8
Neil Swanson	Present for notes 1 – 8

In attendance:		
Agnes Cuyas	Information Specialist, NGC	Present for notes 1- 4
Annabelle Davies	Health Economist, NGC	Present for notes 1 – 8
Rupert Franklin	Senior Guidelines Commissioning Manager, NICE	Present for notes 5 – 8
Saoussen Ftouh	Senior Research Fellow, NGC	Present for notes 1 – 8
Bernard Higgins	Clinical Director and Guideline Lead, NGC	Present for notes 1 – 8
Katherine Jones	Research Fellow, NGC	Present for notes 1 – 8
Sedina Lewis	Research Fellow, NGC	Present for notes 1 – 8
Kate Lovibond	Health Economics Lead, NGC	Present for notes 1 – 8
Ian Mather	Business Analyst – Resource Impact, NICE	Present for notes 1 – 8
Nancy Pursey	Senior Project Manager, NGC	Present for notes 1 – 8

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the fifth meeting of the ACS guideline committee.

The Chair informed the Committee that apologies were received from Muhammad Khan, Alun Roebuck and Jill Cobb. The chair welcomed Sedina Lewis who is joining the team as a research fellow. Katherine Jones is leaving and the chair thanked her for her work on the guideline.

The Chair outlined the objectives of the meeting, which included:

- Draft the protocol for the evidence review for anti-thrombin therapy for adults with unstable angina, non-ST- elevation myocardial infarction (NSTEMI) or ST-elevation myocardial infarction (STEMI).
- Review the evidence for the clinical and cost effectiveness of anti-platelets for managing unstable angina, NSTEMI and STEMI.
- Discuss the feasibility and appropriateness of conducting a network meta-analysis for the dual antiplatelet therapy review.
- Discuss the structure and inputs for original health economic analysis for dual antiplatelet therapy.

2. Confirmation of matter under discussion, and declarations of interest

The Chair asked everyone to verbally declare any interests that have arisen since interests were declared on appointment. Ewan Gittins declared prior to the meeting that he has recently become a member of the British Heart Foundation patient advisory group and will be interviewed for a position on the NHS Innovation Accelerator panel. The register of interests was reviewed prior to the meeting by the Chair and Guideline lead and there were no interests that represented a conflict with the topics under discussion.

3. Minutes of previous meeting

The minutes of the previous meeting were confirmed as an accurate record of the meeting. All actions were completed or in progress.

4. Protocol for anti-thrombin therapy

Saoussen Ftouh presented a draft protocol for anti-thrombin therapy in adults with unstable angina, NSTEMI and STEMI. The committee discussed and amended the protocol. The committee agreed to focus the review on fondaparinux in view of evidence published since the previous guideline. This was the original intention of

this review question but it had not been clearly described by the question on the scope.

5. Evidence review: dual anti-platelet therapy

Katherine Jones presented the clinical evidence and Annabelle Davies presented the cost effectiveness evidence for the review: which antiplatelet is most clinically and cost effective for managing unstable angina or NSTEMI for managing STEMI in adults? The committee discussed the evidence. Recommendations were not drafted pending further work on this question. This topic will be revisited when we have the results of the original health economic analysis and network meta-analysis (see items 6 and 7).

6. Network meta-analysis for dual antiplatelet therapy review

Saoussen Ftouh and Kate Lovibond led a discussion about the feasibility and appropriateness of conducting a network meta-analysis for the dual antiplatelet therapy review. The committee agreed to proceed with the network meta-analysis.

7. Health economics for dual antiplatelet therapy

Annabelle Davies led a discussion about the model for the dual antiplatelet therapy review. The Committee gave feedback on the proposed structure and inputs for the model.

8. AOB

None

Date of next meeting: Tuesday 26 February 2019

Location of next meeting: Royal College of Physicians, London